tldrdailynews.com logo

FDA Approves Wearable TTFields Therapy for Locally Advanced Pancreatic Cancer

1 min read
Source: Medscape
FDA Approves Wearable TTFields Therapy for Locally Advanced Pancreatic Cancer
Photo: Medscape
TL;DR

The FDA approved Optune Pax, a wearable device delivering abdominal tumor treating fields (TTFields) to treat locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, based on PANOVA-3 which showed longer median overall survival and pain-free survival with TTFields versus chemotherapy alone; skin reactions were common; the device costs about $21,000 per month and includes patches, a generator, and support services.

Topics:businesshealth#fda-approval#health#novocure#optune-pax#pancreatic-cancer#ttfields
Share this article
  1. FDA Approves Wearable Device to Treat Pancreatic Cancer  Medscape
  2. Michael Chuong: Humbled to be The First in the U.S. to Prescribe Optune Pax for Pancreatic Cancer  Oncodaily
  3. Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar  The Wall Street Journal
  4. New FDA-approved device to help patients battling pancreatic cancer  News12 | Long Island
  5. Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device  Yahoo Finance

Want the full story? Read the original reporting

Read on Medscape